TET2 and acute myeloid leukemia: Three AML patients with biallelic TET2 mutation were randomized to the low‐dose Ara‐C plus fludarabine (FLUGA) arm, but none of these entered remission, and all had relatively short OS (17, 45, and 111 days) compared to those with monoallelic TET2 mutation.